litlas
ログインアカウント作成

Jeffrey A. Jones

1989–2025 年に発表

98
論文数
20,407
被引用数
69
h 指数
93
i10 指数

被引用数

Jeffrey A. Jones の年別被引用数1896 年: 被引用 1 件1991 年: 被引用 2 件1992 年: 被引用 4 件1993 年: 被引用 6 件1994 年: 被引用 6 件1995 年: 被引用 9 件1996 年: 被引用 11 件1997 年: 被引用 3 件1998 年: 被引用 10 件1999 年: 被引用 4 件2000 年: 被引用 8 件2001 年: 被引用 8 件2002 年: 被引用 14 件2003 年: 被引用 16 件2004 年: 被引用 18 件2005 年: 被引用 52 件2006 年: 被引用 60 件2007 年: 被引用 77 件2008 年: 被引用 64 件2009 年: 被引用 86 件2010 年: 被引用 100 件2011 年: 被引用 95 件2012 年: 被引用 65 件2013 年: 被引用 110 件2014 年: 被引用 196 件2015 年: 被引用 250 件2016 年: 被引用 202 件2017 年: 被引用 267 件2018 年: 被引用 296 件2019 年: 被引用 887 件2020 年: 被引用 868 件2021 年: 被引用 876 件2022 年: 被引用 495 件2023 年: 被引用 331 件2024 年: 被引用 520 件2025 年: 被引用 193 件2026 年: 被引用 6 件1897〜1990 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,242 件、この内訳の 29.7%イギリス: 引用元論文 507 件、この内訳の 6.7%中国: 引用元論文 500 件、この内訳の 6.6%イタリア: 引用元論文 447 件、この内訳の 5.9%ドイツ: 引用元論文 446 件、この内訳の 5.9%フランス: 引用元論文 331 件、この内訳の 4.4%カナダ: 引用元論文 297 件、この内訳の 3.9%オーストラリア: 引用元論文 271 件、この内訳の 3.6%オランダ: 引用元論文 220 件、この内訳の 2.9%スペイン: 引用元論文 212 件、この内訳の 2.8%日本: 引用元論文 177 件、この内訳の 2.3%スイス: 引用元論文 172 件、この内訳の 2.3%
0%29.7%その他 23%

機関

分野

  • Medicine76.1%
  • Biochemistry, Genetics and Molecular Biology15.1%
  • Immunology and Microbiology2.5%
  • Earth and Planetary Sciences1.7%
  • Chemistry1.1%
  • Engineering1.1%
  • その他2.4%

トピック

  • Chronic Lymphocytic Leukemia Research11.9%
  • Lymphoma Diagnosis and Treatment7.5%
  • Prostate Cancer Treatment and Research5%
  • Immunodeficiency and Autoimmune Disorders3%
  • Chronic Myeloid Leukemia Treatments2.5%
  • Prostate Cancer Diagnosis and Treatment2.4%
  • その他67.7%

共著者

全論文

検索で開く
  1. Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

    著者: John C. Byrd, Richard R. Furman, Steven Coutré, Ian W. Flinn, Jan A. Burger, Kristie A. Blum, Barbara Grant, Jeff P. Sharman, Morton Coleman, William G. Wierda, Jeffrey A. Jones, Weiqiang Zhao, Nyla A. Heerema, Amy J. Johnson, Juthamas Sukbuntherng, Betty Chang, Fong Clow, Eric Hedrick, Joseph J. Buggy, Danelle F. James, Susan O’Brien - New England Journal of Medicine 2013 被引用: 2,249

  2. Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer

    著者: Daniel P. Petrylak, Catherine M. Tangen, Maha Hussain, Primo N. Lara, Jeffrey A. Jones, Mary Ellen Taplin, Patrick A. Burch, Donna L. Berry, Carol M. Moinpour, Manish Kohli, Mitchell C. Benson, Eric J. Small, Derek Raghavan, E. David Crawford - New England Journal of Medicine 2004 被引用: 3,687

  3. BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia

    著者: Jennifer A. Woyach, Amy S. Ruppert, Daphne Guinn, Amy Lehman, James S. Blachly, Arletta Lozanski, Nyla A. Heerema, Weiqiang Zhao, Joshua F. Coleman, Daniel Jones, Lynne V. Abruzzo, Amber Gordon, Rose Mantel, Lisa L. Smith, Samantha McWhorter, Melanie E. Davis, Tzyy-Jye Doong, Fan Ny, Margaret S. Lucas, Weihong Chase, Jeffrey A. Jones, Joseph M. Flynn, Kami J. Maddocks, Kerry A. Rogers, Samantha Jaglowski, Leslie A. Andritsos, Farrukh T. Awan, Kristie A. Blum, Michael R. Grever, Gerard Lozanski, Amy J. Johnson, John C. Byrd - Journal of Clinical Oncology 2017 被引用: 471

  4. Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia

    著者: John C. Byrd, Bonnie K. Harrington, Susan O’Brien, Jeffrey A. Jones, Anna Schuh, Steve Devereux, Jorge Chaves, William G. Wierda, Farrukh T. Awan, Jennifer R. Brown, Peter Hillmen, Deborah M. Stephens, Paolo Ghia, Jacqueline C. Barrientos, John M. Pagel, Jennifer A. Woyach, Dave Johnson, Jane Huang, Xiaolin Wang, Allard Kaptein, Brian J. Lannutti, Todd Covey, Maria Fardis, Jesse McGreivy, Ahmed Hamdy, Wayne Rothbaum, Raquel Izumi, Thomas G. Diacovo, Amy J. Johnson, Richard R. Furman - New England Journal of Medicine 2015 被引用: 891

  5. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

    著者: Jason A. Dubovsky, Kyle A. Beckwith, Gayathri Natarajan, Jennifer A. Woyach, Samantha Jaglowski, Yiming Zhong, Joshua Hessler, Ta-Ming Liu, Betty Chang, Karilyn M. Larkin, Matthew Stefanovski, Danielle L. Chappell, Frank Frissora, Lisa L. Smith, Kelly A. Smucker, Joseph M. Flynn, Jeffrey A. Jones, Leslie A. Andritsos, Kami J. Maddocks, Amy M. Lehman, Richard R. Furman, Jeff P. Sharman, Anjali Mishra, Michael A. Caligiuri, Abhay R. Satoskar, Joseph J. Buggy, Natarajan Muthusamy, Amy J. Johnson, John C. Byrd - Blood 2013 被引用: 796

  6. Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia

    著者: Kami J. Maddocks, Amy S. Ruppert, Gerard Lozanski, Nyla A. Heerema, Weiqiang Zhao, Lynne V. Abruzzo, Arletta Lozanski, Melanie E. Davis, Amber Gordon, Lisa L. Smith, Rose Mantel, Jeffrey A. Jones, Joseph M. Flynn, Samantha Jaglowski, Leslie A. Andritsos, Farrukh T. Awan, Kristie A. Blum, Michael R. Grever, Amy J. Johnson, John C. Byrd, Jennifer A. Woyach - JAMA Oncology 2015 被引用: 576

  7. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial

    著者: Jeffrey A. Jones, Anthony R. Mato, William G. Wierda, Matthew S. Davids, Michael Y. Choi, Bruce D. Cheson, Richard R. Furman, Nicole Lamanna, Paul M. Barr, Lang Zhou, Brenda Chyla, Ahmed Hamed Salem, Maria Verdugo, Rod Humerickhouse, Jalaja Potluri, Steven Coutré, Jennifer A. Woyach, John C. Byrd - The Lancet Oncology 2017 被引用: 378

  8. Ibrutinib treatment improves T cell number and function in CLL patients

    著者: Meixiao Long, Kyle A. Beckwith, Priscilla Do, Bethany L. Mundy-Bosse, Amber Gordon, Amy M. Lehman, Kami J. Maddocks, Carolyn Cheney, Jeffrey A. Jones, Joseph M. Flynn, Leslie A. Andritsos, Farrukh T. Awan, Joseph A. Fraietta, Carl H. June, Marcela V. Maus, Jennifer A. Woyach, Michael A. Caligiuri, Amy J. Johnson, Natarajan Muthusamy, John C. Byrd - Journal of Clinical Investigation 2017 被引用: 377

  9. Ventricular arrhythmias and sudden death in patients taking ibrutinib

    著者: Benjamin L. Lampson, Lijian Yu, Robert J. Glynn, Jacqueline C. Barrientos, Eric D. Jacobsen, Versha Banerji, Jeffrey A. Jones, Renata Walewska, Kerry J. Savage, Gregory F. Michaud, Javid J. Moslehi, Jennifer R. Brown - Blood 2017 被引用: 209

  10. Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non–Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions

    著者: Zofia Piotrowska, Daniel S.W. Tan, Egbert F. Smit, Alexander I. Spira, Ross A. Soo, Danny Nguyen, Victor Lee, James Chih‐Hsin Yang, Vamsidhar Velcheti, John Wrangle, Mark A. Socinski, Marianna Koczywas, John E. Janik, Jeffrey A. Jones, Helena A. Yu - Journal of Clinical Oncology 2023 被引用: 56

  11. Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation

    著者: Ta-Ming Liu, Jennifer A. Woyach, Yiming Zhong, Arletta Lozanski, Gerard Lozanski, Shuai Dong, Ethan Strattan, Amy Lehman, Xiaoli Zhang, Jeffrey A. Jones, Joseph M. Flynn, Leslie A. Andritsos, Kami J. Maddocks, Samantha Jaglowski, Kristie A. Blum, John C. Byrd, Jason A. Dubovsky, Amy J. Johnson - Blood 2015 被引用: 174

  12. Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies

    著者: Ian W. Flinn, Susan O’Brien, Brad S. Kahl, Manish R. Patel, Yasuhiro Oki, Francine F. Foss, Pierluigi Porcu, Jeffrey A. Jones, Jan A. Burger, Nitin Jain, Virginia Kelly, Kerstin Allen, Mark Douglas, Jennifer Sweeney, Patrick Kelly, Steven M. Horwitz - Blood 2017 被引用: 253

  13. Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia

    著者: Kerry A. Rogers, Ying Huang, Amy S. Ruppert, Lynne V. Abruzzo, Barbara L. Andersen, Farrukh T. Awan, Seema A. Bhat, Allison Dean, Margaret S. Lucas, Christin Banks, Cara Grantier, Nyla A. Heerema, Gerard Lozanski, Kami J. Maddocks, Thomas R Valentine, David M. Weiss, Jeffrey A. Jones, Jennifer A. Woyach, John C. Byrd - Journal of Clinical Oncology 2020 被引用: 104

  14. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib

    著者: John C. Byrd, Richard R. Furman, Steven Coutré, Jan A. Burger, Kristie A. Blum, Morton Coleman, William G. Wierda, Jeffrey A. Jones, Weiqiang Zhao, Nyla A. Heerema, Amy J. Johnson, Yun Shaw, Elizabeth Bilotti, Cathy Zhou, Danelle F. James, Susan O’Brien - Blood 2015 被引用: 656

  15. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study

    著者: Susan O’Brien, Jeffrey A. Jones, Steven Coutré, Anthony R. Mato, Peter Hillmen, Constantine S. Tam, Anders Österborg, Tanya Siddiqi, Michael J. Thirman, Richard R. Furman, Osman İlhan, Michael J. Keating, Timothy G. Call, Jennifer R. Brown, Michelle Stevens-Brogan, Yunfeng Li, Fong Clow, Danelle F. James, Alvina D. Chu, Michael Hallek, Stephan Stilgenbauer - The Lancet Oncology 2016 被引用: 339

  16. Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib

    著者: Tracy Wiczer, Lauren Levine, Jessica Brumbaugh, Jessica Coggins, Qiuhong Zhao, Amy S. Ruppert, Kerry A. Rogers, Anli McCoy, Luay Mousa, Avirup Guha, Nyla A. Heerema, Kami J. Maddocks, Beth Christian, Leslie A. Andritsos, Samantha Jaglowski, Steven M. Devine, Robert A. Baiocchi, Jennifer A. Woyach, Jeffrey A. Jones, Michael R. Grever, Kristie A. Blum, John C. Byrd, Farrukh T. Awan - Blood Advances 2017 被引用: 162

  17. High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia

    著者: Bing Cui, Emanuela M. Ghia, Liguang Chen, Laura Z. Rassenti, Christopher DeBoever, George F. Widhopf, Jian Yu, Donna Neuberg, William G. Wierda, R. Kanti, Neil E. Kay, Jennifer R. Brown, Jeffrey A. Jones, John G. Gribben, Kelly A. Frazer, Thomas J. Kipps - Blood 2016 被引用: 144

  18. Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience

    著者: Susan O’Brien, Richard R. Furman, Steven Coutré, Ian W. Flinn, Jan A. Burger, Kristie A. Blum, Jeff P. Sharman, William G. Wierda, Jeffrey A. Jones, Weiqiang Zhao, Nyla A. Heerema, Amy J. Johnson, Ying Luan, Danelle F. James, Alvina D. Chu, John C. Byrd - Blood 2018 被引用: 387

  19. Pathophysiology and Pathogenesis of Marfan Syndrome

    著者: Sanford Zeigler, Brandon Sloan, Jeffrey A. Jones - Advances in experimental medicine and biology 2021 被引用: 109

  20. Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA — update 2018

    著者: Yair Lotan, Trinity J. Bivalacqua, Tracy M. Downs, William C. Huang, Jeffrey A. Jones, Ashish M. Kamat, Badrinath R. Konety, Per‐Uno Malmström, James McKiernan, Michael A. O’Donnell, Sanjay Patel, Kamal S. Pohar, Matthew J. Resnick, Alexander Sankin, Angela B. Smith, Gary D. Steinberg, Edouard J. Trabulsi, Michael Woods, Siamak Daneshmand - Nature Reviews Urology 2019 被引用: 83

  21. Space Radiation and Cataracts in Astronauts

    著者: Francis A. Cucinotta, F. K. Manuel, Jeffrey A. Jones, G. Iszard, J. Murrey, B. Djojonegro, Mary L. Wear - Radiation Research 2001 被引用: 391

  22. Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

    著者: Matthew S. Davids, Michael Hallek, William G. Wierda, Andrew W. Roberts, Stephan Stilgenbauer, Jeffrey A. Jones, John F. Gerecitano, Su Young Kim, Jalaja Potluri, Todd Busman, Andrea Best, Maria E. Verdugo, Elisa Cerri, Monali Desai, Peter Hillmen, John F. Seymour - Clinical Cancer Research 2018 被引用: 161

  23. Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy

    著者: Steven Coutré, Michael Y. Choi, Richard R. Furman, Herbert Eradat, Leonard T. Heffner, Jeffrey A. Jones, Brenda Chyla, Lang Zhou, Suresh Agarwal, Tina Waskiewicz, Maria Verdugo, Rod Humerickhouse, Jalaja Potluri, William G. Wierda, Matthew S. Davids - Blood 2018 被引用: 132

  24. Space Radiation Protection Countermeasures in Microgravity and Planetary Exploration

    著者: Carlos A. Montesinos, Radina Khalid, Octav Cristea, Joel S. Greenberger, Michael W. Epperly, Jennifer A. Lemon, Douglas R. Boreham, Dmitri Popov, Gitika Gorthi, Nandita Ramkumar, Jeffrey A. Jones - Life 2021 被引用: 71